UroGen Pharma Profit Margin

The latest profit margin for URGN is -51.73% as of June 2026. That compares with -164.44% in the prior-year period — up 68.5% year over year. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside UroGen Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, URGN's profit margin moved from -164.44% to -51.73% — a 68.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in UroGen Pharma's valuation or profitability profile.

Against Healthcare companies, URGN currently prints -51.73% for profit margin, while the sector average sits near 14.34%. That is roughly 460.6% below the sector mean. Large gaps often invite a closer look at UroGen Pharma's growth, margins, and balance sheet.

Profit Margin shows how effectively UroGen Pharma converts resources into returns. At -51.73%, URGN may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -164.44% in the prior-year period — up 68.5% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting URGN's profit margin (-51.73%), review year-over-year change from -164.44%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.